GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KPC Pharmaceuticals Inc (SHSE:600422) » Definitions » Gross Profit

KPC Pharmaceuticals (SHSE:600422) Gross Profit : ¥3,651 Mil (TTM As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is KPC Pharmaceuticals Gross Profit?

KPC Pharmaceuticals's gross profit for the three months ended in Dec. 2024 was ¥1,419 Mil. KPC Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was ¥3,651 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. KPC Pharmaceuticals's gross profit for the three months ended in Dec. 2024 was ¥1,419 Mil. KPC Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was ¥2,944 Mil. Therefore, KPC Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2024 was 48.18%.

KPC Pharmaceuticals had a gross margin of 48.18% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of KPC Pharmaceuticals was 49.89%. The lowest was 34.50%. And the median was 43.31%.


KPC Pharmaceuticals Gross Profit Historical Data

The historical data trend for KPC Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KPC Pharmaceuticals Gross Profit Chart

KPC Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,330.39 3,408.76 3,438.37 3,929.35 3,651.25

KPC Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,401.02 763.09 697.91 771.74 1,418.51

Competitive Comparison of KPC Pharmaceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KPC Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where KPC Pharmaceuticals's Gross Profit falls into.



KPC Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

KPC Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=8401.447 - 4750.196
=3,651

KPC Pharmaceuticals's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=2943.992 - 1525.485
=1,419

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,651 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

KPC Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=1,419 / 2943.992
=48.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


KPC Pharmaceuticals  (SHSE:600422) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

KPC Pharmaceuticals had a gross margin of 48.18% for the quarter that ended in Dec. 2024 => Durable competitive advantage


KPC Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of KPC Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


KPC Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
Executives
Qu Xiao Ru senior management
Xie Bo senior management
Meng Li senior management
Zhong Xiang Gang senior management
Wu Sheng Long senior management
Liu Jun Feng senior management
Wang Lei senior management
Zhang Meng Xun senior management
Hu Zhen Bo senior management
Sun Lei senior management
Xu Chao Neng senior management
Wang Jun senior management
Zhao Jian senior management
He Qin Director
Dai Xiao Chang senior management

KPC Pharmaceuticals Headlines

No Headlines